Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase in...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Bilic, Sanela Cameron, John Scott Howard Jr., Danny Roland |
| description | C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase inhibitor 5 or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of 10 proliferative disease; and a commercial package comprising such combination. UHcI2 HH Mn M > M N& ~~P:4 H4 H H4 O 4 E4 E4 1 co a M M >D > m9( UU)U)C 0, 00F >> coc > > Fl Fl rm FZ P P 4 04 Ei 2' 0 U)U 00M M > > 00 U)U > HH> H m~ ~ oY M M p Cf Q 00 U)U< - O I-HI-H 00O 00e HH< B U)>> |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2020201057A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2020201057A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2020201057A13</originalsourceid><addsrcrecordid>eNqNirEKwjAQQLM4iPoPB86BRhHnUhUXxUHnkqQXcpDmSnNF_HsV_AB5wxvem6trw72jbIU4Awfw-oIClCM5Eh7hSRLBZiHH3Qt6TuinhCAMt4M2n9LBVLCARByRw1LNgk0FVz8v1Pp0vDdnjQO3WAbrMaO09WNTfTHVbl-b7X_XG2wONjI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof</title><source>esp@cenet</source><creator>Bilic, Sanela ; Cameron, John Scott ; Howard Jr., Danny Roland</creator><creatorcontrib>Bilic, Sanela ; Cameron, John Scott ; Howard Jr., Danny Roland</creatorcontrib><description><![CDATA[C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase inhibitor 5 or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of 10 proliferative disease; and a commercial package comprising such combination. UHcI2 HH Mn M <J 4 D 0 0 HHl 00 00 & H HH F1 o 4 04Ot 00 : ,F H MHJi HMI L > > M N& ~~P:4 H4 H H4 O 4 E4 E4 <l 0 64 DD:-i: N N : o 0 64 Q nt UD ) 09 at 00 w w O1 >1 co a M M >D > m9( UU)U)C 0, 00F >> coc > > Fl Fl rm FZ P P 4 04 Ei 2' 0 U)U 00M M <r < n U M U U U U F U ) E oq o p p E E > > > 00 U)U > HH> H m~ ~ oY M M p Cf Q 00 U)U< - O I-HI-H 00O 00e HH< B U)>>]]></description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200305&DB=EPODOC&CC=AU&NR=2020201057A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200305&DB=EPODOC&CC=AU&NR=2020201057A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Bilic, Sanela</creatorcontrib><creatorcontrib>Cameron, John Scott</creatorcontrib><creatorcontrib>Howard Jr., Danny Roland</creatorcontrib><title>Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof</title><description><![CDATA[C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase inhibitor 5 or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of 10 proliferative disease; and a commercial package comprising such combination. UHcI2 HH Mn M <J 4 D 0 0 HHl 00 00 & H HH F1 o 4 04Ot 00 : ,F H MHJi HMI L > > M N& ~~P:4 H4 H H4 O 4 E4 E4 <l 0 64 DD:-i: N N : o 0 64 Q nt UD ) 09 at 00 w w O1 >1 co a M M >D > m9( UU)U)C 0, 00F >> coc > > Fl Fl rm FZ P P 4 04 Ei 2' 0 U)U 00M M <r < n U M U U U U F U ) E oq o p p E E > > > 00 U)U > HH> H m~ ~ oY M M p Cf Q 00 U)U< - O I-HI-H 00O 00e HH< B U)>>]]></description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNirEKwjAQQLM4iPoPB86BRhHnUhUXxUHnkqQXcpDmSnNF_HsV_AB5wxvem6trw72jbIU4Awfw-oIClCM5Eh7hSRLBZiHH3Qt6TuinhCAMt4M2n9LBVLCARByRw1LNgk0FVz8v1Pp0vDdnjQO3WAbrMaO09WNTfTHVbl-b7X_XG2wONjI</recordid><startdate>20200305</startdate><enddate>20200305</enddate><creator>Bilic, Sanela</creator><creator>Cameron, John Scott</creator><creator>Howard Jr., Danny Roland</creator><scope>EVB</scope></search><sort><creationdate>20200305</creationdate><title>Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof</title><author>Bilic, Sanela ; Cameron, John Scott ; Howard Jr., Danny Roland</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2020201057A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2020</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Bilic, Sanela</creatorcontrib><creatorcontrib>Cameron, John Scott</creatorcontrib><creatorcontrib>Howard Jr., Danny Roland</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bilic, Sanela</au><au>Cameron, John Scott</au><au>Howard Jr., Danny Roland</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof</title><date>2020-03-05</date><risdate>2020</risdate><abstract><![CDATA[C:\Interwove\NRPortb\DCC\SXD\19865606_l.doc-13/02/2020 The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1) , and (b) at least one c-Met receptor tyrosine kinase inhibitor 5 or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of 10 proliferative disease; and a commercial package comprising such combination. UHcI2 HH Mn M <J 4 D 0 0 HHl 00 00 & H HH F1 o 4 04Ot 00 : ,F H MHJi HMI L > > M N& ~~P:4 H4 H H4 O 4 E4 E4 <l 0 64 DD:-i: N N : o 0 64 Q nt UD ) 09 at 00 w w O1 >1 co a M M >D > m9( UU)U)C 0, 00F >> coc > > Fl Fl rm FZ P P 4 04 Ei 2' 0 U)U 00M M <r < n U M U U U U F U ) E oq o p p E E > > > 00 U)U > HH> H m~ ~ oY M M p Cf Q 00 U)U< - O I-HI-H 00O 00e HH< B U)>>]]></abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2020201057A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A20%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Bilic,%20Sanela&rft.date=2020-03-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2020201057A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |